Article

VIDEO: Beckie Fenrick, PharmD, MBA, Speaks about Oncolytic Therapies

Conference|AMCP: The Academy of Managed Care Pharmacy

In this video, Beckie Fenrick, PharmD, MDA, Senior Director, Medical Operations, Care Models and Affordability Solutions, Florida Blue, speaks about oncoloytic therapies. In particular, Fenrick talks about new strategies for managing oncolytic therapies without sacrificing outcomes.

In this video, Beckie Fenrick, PharmD, MDA, Senior Director, Medical Operations, Care Models and Affordability Solutions, Florida Blue, speaks about oncoloytic therapies. In particular, Fenrick talks about new strategies for managing oncolytic therapies without sacrificing outcomes.

This video was taken on Friday, April 20, 2012, at the 24th Annual Academy of Managed Care Pharmacy Conference in San Francisco, CA.

Related Videos
Picture of San Diego skyline with words ASH Annual Meeting 2024 and health icons overlaid on the bottom
Screenshot of an interview with Amir Ali, PharmD, BCOP
Mansi Shah, MD, assistant professor, Rutgers Cancer Institute of New Jersey
Alvaro Alencar, MD, associate professor of clinical medicine, chief medical officer, University of Miami Sylvester Comprehensive Cancer Center
Dr Cesar Davila-Chapa
Screenshot of an interview with Nadine Barrett, PhD
Milind Desai, MD
Masanori Aikawa, MD
Neil Goldfarb, GPBCH
Mabel Mardones, MD.
Related Content
Chromosomes with Telomere floating on blue background | Image credit: peterschreiber.media – stock.adobe.com
January 21st 2025

Venetoclax Shows Good Results Even in Short-Telomere Patients With CLL

Jared Kaltwasser
New data suggest venetoclax may offset the negative prognostic impact of short telomeres in patients with chronic lymphocytic leukemia (CLL).
Image of Managed Care Cast logo
August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw
At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Psoriatic arthritis | Image Credit: © Andrii-stock.adobe.com
January 15th 2025

Pain, Fatigue With Bimekizumab for PsA Tied to Swollen Joints

Maggie L. Shaw
Bimekizumab (Bimzelx; UCB Pharma) was approved by the FDA to treat psoriatic arthritis (PsA) on September 23, 2024, based on data from 2 phase 3 trials: BE OPTIMAL and BE COMPLETE.
Managed Care Cast.
June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia
On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Marie-France Jilderda, MD, PhD Candidate Surgical Oncology at Leiden University Medical Center in the Netherlands.
January 15th 2025

BCI Shows Promise of Personalized Endocrine Therapy in Breast Cancer

Cameron Santoro
The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially lower health care costs.
MDS blood test | Image credit: MdBabul - stock.adobe.com
January 13th 2025

Targeted Treatment May Improve Outcomes in IDH1-Mutated MDS

AJMC Contributor
A pair of abstracts presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exhibition suggest that IDH1-targeted treatment may improve survival among patients with myelodysplastic syndromes (MDS) with the mutation.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo